Can a weight-loss injection help an arthritic knee?

This is the question I expect many patients to ask after the latest headlines, and the honest answer has several parts. In a large trial, an investigational medicine called retatrutide did lessen knee osteoarthritis pain in people living with obesity. [1] It has not been shown to rebuild cartilage, and it is not a licensed option in the UK at present. [2]

In short: the pain result is real for the group studied, the cartilage question is unanswered, and the drug is investigational, not MHRA-authorised in the UK. [1] [2]

I am writing as a clinician who has spent years thinking about how to keep a patient's own joint working for longer. These findings interest me, and I also want to be careful about what they allow us to say.

What the TRIUMPH-1 trial found

The trial included a knee osteoarthritis subgroup of people with obesity. Over 80 weeks, those given retatrutide reported a significantly larger improvement in WOMAC knee pain than those given placebo. WOMAC is a standard questionnaire that scores osteoarthritis symptoms such as pain. [1] Put simply, retatrutide reduced knee osteoarthritis pain in people with obesity in the TRIUMPH-1 trial over 80 weeks.

Two cautions follow. First, the source I am citing is a manufacturer's conference presentation, so it deserves the careful reading we give any early report. [1] Second, the result applies to the people who were studied. A healthy-weight person with a focal cartilage injury or a meniscal tear was not the subject, and an average across a group cannot tell any one individual what to expect.

It follows that nobody should assume this drug suits every person with a sore knee, or that it repairs the joint. Retatrutide is investigational, and it is not authorised by the MHRA in the UK. [2]

Does it regenerate cartilage?

No, and the results do not establish cartilage regeneration. Pain can fall without any new cartilage forming. Nothing in the knee findings shows that retatrutide regrows cartilage, reverses arthritis or averts a knee replacement. [1]

Because my own field includes regenerative medicine, I am strict about this wording. Less pain is a worthwhile benefit on its own terms. Whether better metabolic health might one day improve the results of cartilage repair is a separate research question, and these trials have not addressed it.

Why weight and metabolism matter for the knee

Osteoarthritis is often called wear and tear, a phrase I have never found satisfying. The knee is living tissue. How it feels depends on cartilage and bone, but also on the synovium (the joint lining), the muscles around it, the forces passing through it, inflammation, body composition and overall metabolic health.

Excess weight shows this well. Extra body mass raises the load through the knee, yet the link between obesity and osteoarthritis is not only mechanical. Fat tissue is metabolically active, and metabolic and inflammatory pathways increasingly feature in current thinking about the disease.

For that reason I think of a broader aim than lowering the number on the scales: better metabolic health, less excess fat, muscle kept or improved, better movement, and care for the joint itself where that is needed.

How retatrutide works, in plain terms

Retatrutide is a triple receptor agonist. It acts on GLP-1, GIP and glucagon receptors, so a single medicine engages three hormone pathways that are involved in metabolism. [3]

The three pathways

GLP-1 helps control appetite and supports the release of insulin when blood glucose is high. GIP also promotes insulin release that depends on glucose. Retatrutide adds activity at the glucagon receptor to these two effects. [3]

Glucagon and insulin should not be confused, because they do different jobs. Insulin helps the body use and store glucose: it moves glucose from the blood into tissues such as muscle and lowers the amount the liver produces. Glucagon keeps blood glucose steady between meals by prompting the liver to release glucose, and it also affects fat and amino-acid metabolism. Retatrutide does not behave like insulin. It switches on GLP-1, GIP and glucagon receptors together, giving a combined metabolic effect.

Why the glucagon part draws interest

Glucagon may add to the energy the body burns and change how it handles fuel. In early laboratory work, retatrutide raised energy expenditure in mice through a glucagon-related effect. That explains the thinking behind the design, though it does not tell us how much this contributes to lasting weight loss in people. [3]

I would resist saying that glucagon directly activates muscle. Human evidence that retatrutide switches on or strengthens skeletal muscle does not exist at present.

Muscle matters during weight loss

Even so, muscle must be part of the discussion. When someone loses a lot of weight, I do not want them to end up as a smaller version of the same patient. I want to know how their muscle, strength and movement are faring.

This matters a great deal for the knee. The quadriceps take up load, steady the joint and let you stand, walk and manage stairs. Shedding fat helps the knee only if useful muscle is not being lost along the way.

A human body-composition substudy of retatrutide, in people with type 2 diabetes, recorded a loss of lean tissue alongside fat loss, in a proportion that the authors describe as similar to other obesity treatments. Lean tissue is not the same thing as skeletal muscle, and a scan of body composition cannot show whether strength has changed. So the study gives no grounds to claim that muscle is automatically protected. [4]

My view is that any metabolic approach to osteoarthritis should include objective checks of muscle and movement. Sensible nutrition and suitable exercise stay important whenever weight loss is medically supervised. [2]

Looking beyond the scales

Imagine following a patient with knee osteoarthritis using more than a pain score and a weight. We could track:

• body composition and metabolic health;
• muscle strength and day-to-day capacity;
• walking, squatting and getting up from a chair;
• knee symptoms;
• imaging and joint structure when appropriate; and
• whether the person is becoming more capable instead of just lighter.

That is the heart of joint preservation as I see it. The useful question stops being how much weight was lost and becomes this:

Have we given your knee a healthier biological and mechanical setting?

I use the phrase metabolic joint preservation only as a description of a clinical goal, which is to weigh metabolic health together with symptoms, strength and the joint. It does not claim that retatrutide protects cartilage structure.

Where this could lead, and what to do now

Might metabolic treatment become part of routine care for knee osteoarthritis? I think it may. That is my reading of the direction of travel, and it has not been proven. Retatrutide is not an approved treatment for knee osteoarthritis, and current trials do not demonstrate cartilage regeneration or disease modification.

For selected patients who have both knee arthritis and metabolic disease or excess weight, future care may treat the joint and its metabolic surroundings together. That could involve nutrition, medically supervised weight management where suitable, protecting muscle, progressive strengthening, better movement and targeted treatment of the knee.

In the meantime, nobody needs to wait. A painful knee still deserves to be assessed, using the options available now, and MSK Doctors assesses knee osteoarthritis on that basis.

References and further reading

The first source below is a conference presentation from the manufacturer. The two Coskun papers address other questions, namely the drug's mechanism and its effect on body composition.

1. Lilly: TRIUMPH-1 Phase 3 results, ADA Scientific Sessions, June 2026 (conference presentation).
2. MHRA: No summer shortcut for safe weight loss, 24 July 2026.
3. Coskun et al. LY3437943: from discovery to clinical proof of concept. Cell Metabolism, 2022.
4. Coskun et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 randomised trial. Lancet Diabetes & Endocrinology, 2025.